Interleukin-18 levels reflect the long-term prognosis of acute lung injury and acute respiratory distress syndrome

Journal of Anesthesia

Volumn 26, Issue 5, 2012, Pages 658-663

  Makabe, Hideyuki ^a   Kojika, Masahiro ^a   Takahashi, Gaku ^a   Matsumoto, Naoya ^a   Shibata, Shigehiro ^a   Suzuki, Yasushi ^a   Inoue, Yoshihiro ^a   Endo, Shigeatsu ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

ALI; ARDS; Interleukin 18; Prognosis; Sepsis

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 18; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LUNG INJURY; ACUTE RESPIRATORY FAILURE; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; APACHE; ARTICLE; CAUSE OF DEATH; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HUMAN; LONG TERM CARE; LUNG ALVEOLUS OXYGEN TENSION; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; MULTIPLE TRAUMA; PERITONITIS; PNEUMONIA; PROGNOSIS; SEPSIS; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SOFT TISSUE INFECTION; SURVIVAL; SURVIVAL RATE; SURVIVOR; BLOOD;

ACUTE LUNG INJURY; AGED; FEMALE; HUMANS; INTERLEUKIN-12; INTERLEUKIN-18; MALE; PROGNOSIS; RESPIRATORY DISTRESS SYNDROME, ADULT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878628043     PISSN: 09138668     EISSN: 14388359     Source Type: Journal    
DOI: 10.1007/s00540-012-1409-3     Document Type: Article

References (35)

1. Nakamura K, Okamura H, Nagata K, Komatsu T, Tamura T. Purification of a factor which provides a costimulatory signal for gamma interferon production. Infect Immunol. 1993;61:64-70.
2. Okamura H, Tsutsui H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe T, Okura T, Nukada Y, Hattori K, Akita K, Namba M, Tanabe F, Konishi K, Fukuda S, Kurimoto M. Cloning of a new cytokine that induces IFN-γ production by T cells. Nature (Lond). 1995;378:88-91.
3. Tsutsui H, Matsui K, Kawada N, Hyodo Y, Hayashi N, Okamura H, HIgashino K, Nakanishi K. IL-18 accounts for both TNF-α and Fas ligand-mediated hepatotoxic pathway in endotoxin-induced liver injury in mice. J Immunol. 1997;159:3961-7.
4. Endo S, Inada K, Yamada Y, Wakabayashi G, Ishikura H, Tanaka T, Sato S. Interleukin 18 (IL-18) levels in patients with sepsis. J Med. 2000;31:15-20.
5. Endo S, Sato, Inoue Y, Fujino Y, Wakabayashi G, Inada K, Sato S. Interleukin 18 levels reflect the severity of acute pancreatitis. Res Mol Pathol Pharmacol 2001;110:285-91.
6. Nakae H, Zheng Y-J, Wada, Tajimi K, Endo S. Involvement of IL-18 and soluble Fas in patients with postoperative hepatic failure. Eur Surg Res. 2003;35:61-6.
7. Pohan HT, Suhendro BR, Matondang AH, Djauzi S, Inada K, Endo S. Interleukin-18 levels in adult dengue fever and dengue hemorrhagic fever. Med J Indonesia. 2004;13:86-9.
8. Imai S, Sato N, Inoue Y, Endo S. A study of interleukin 18 and sFas in septic multiple organ dysfunction syndrome. J Iwate Med Assoc. 2005;57:497-503.
9. Shinoda M, Wakabayashi G, Shimazu M, Saito H, Hoshino K, Tanabe M, Morikawa Y, Endo S, Ishii H, Kitajima M. Increased serum and hepatic tissue levels of interleukin-18 in patients with fulminant hepatic failure. J Gastroenterol Hepatol. 2006;21:1731-6.
10. Jordan JA, Guo R-F, Yun EC, Sarma V, Warner RL, Crouch LD, Senaldi G, Ulich TR, Ward PA. Role of IL-18 in acute lung inflammation. J Immunol. 2001;167:7060-8.
11. Endo S, Sato N, Suzuki Y, Kojika M, Ogawa M, Imai S, Takahashi G, Hakozaki M, Miyata M, Kikuchi S, Yaegashi Y. Effective therapy for IL-18 and P/F ratio treated with PMX-DHP; A case report (in Japanese with English abstract). Jpn J Crit Care Endotoxemia. 2006;10:162-8.
12. Hoshikawa K, Kojika M, Kikkawa T, Akitomi S, Matsumoto N, Takahashi G, Aoki K, Suzuki Y, Endo S. A study of interleukin 18 levels in a patient with septic ARDS: a case report. Med Postgrad 2009;47:265-8 (in Japanese with English abstract).
13. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1644-55/Crit Care Med 1992;20:864-74.
14. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R. The American-European consensus conference on ARDS. Definition, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149:818-24.
15. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. A severity of disease classification system. Crit Care Med. 1985;13:818-29.
16. Vincent JL. Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG. Use of the SOFA score to asses the incidence of organ dysfunction/failure in intensive care units: results of a multicentre, prospective study. Crit Care Med 1998;26:1793-800.
17. Marks JD, Marks CB, Luce JM, Montgomery AB, Turner J, Metz CA, Murray JF. Plasma tumor necrosis factor in patients with septic shock: mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration. Am Rev Respir Dis. 1990;141:94-7.
18. Chang SW. Endotoxin-induced pulmonary leukostasis in the rat: role of platelet-activating factor and tumor necrosis factor. J Lab Clin Med. 1994;123:65-72.
19. Tsutsui H, Nakanishi K, Matsui K, Higashino K, Okamura H, Miyazawa Y, Kaneda K. IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J Immunol. 1996;157:3967-73.
20. Puren AJ, fantuzzi G, Gu Y, Su MS, Dinarello CA. Interleukin 18 (IFN-gamma-inducing factor) induces IL-8 and IL-1 beta via TNF-alpha production from non-CD14+ human blood mononuclear cells. J Clin Invest. 1998;101:711-21.
21. Takahashi G, Endo S, Sato N, Kojika M, Hakozaki M, Imai S, Miyata M, Suga Y, Suzuki Y, Wakabayashi G. Clinical significance of interleukin 18 in cases of multiple organ dysfunction syndromes associated with diffuse peritonitis. J Iwate Med Assoc. 2006;58:23-9.
22. Okamoto M, Kato S, Oizumi K, Kinoshita M, Inoue Y, Hoshino K, Akira S, McKenzie AN, Young HA, Hoshino T. Interleukin 18 (IL-18) in synergy with IL-12 induces lethal lung injury in mice: a potential role for cytokines, chemokines, and natural killer cells in the pathogenesis of interstitial pneumonia. Blood. 2002;99:1289-98.
23. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, Stern EJ, Hudson LD. Incidence and outcomes of acute lung injury. N Engl J Med. 2005;353:1685-93.
24. Luhr OR, Antonsen K, Karlsson M, Aardal S, Thorsteinsson A, Frostell CG, Bonde J. Incidence and mortality after acute respiratory failure and acute respiratory distress syndrome in Sweden, Denmark, and Iceland. The ARF Study Group. Am J Respir Crit Care Med. 1999;159:1849-61.
25. Bersten AD, Edibam C, Hunt T, Australian and New Zealand Intensive Care Society Clinical Trials Group. Incidence and mortality of acute lung injury and the acute respiratory distress syndrome in three Australian States. Am J Respir Crit Care Med. 2002;165:443-8.
26. Takeda S, Ishizaka A, Fujino Y, Fukuoka T, Nagano O, Yamada Y, Takezawa J, Multi-Center Clinical Trial Committee, Japanese Society of Respiratory Care Medicine. Time to change diagnostic criteria of ARDS: toward the disease entity-based subgrouping. Pulm Pharmacol Ther. 2005;18:115-9.
27. Vincent JL, Sakr Y, Groeneveld J, Zandstra DF, Hoste E, Malledant Y, Lei K, Sprung CL. ARDS of early or late onset: does it make a difference? Chest. 2010;137:81-7.
28. Doyle RL, Szaflarski N, Modin GW, Wiener-Kronish JP, Matthay MA. Identification of patients with acute lung injury. Predictors of mortality. Am J Respir Crit Care Med. 1995;152:1818-24.
29. Sloane PJ, Gee MH, Gottlieb JE, Albertine KH, Peters SP, Burns JR, Machiedo G, Fish JE. A multicenter registry of patients with acute respiratory distress syndrome: physiology and outcome. Am Rev Respir Dis. 1992;146:419-26.
30. Vasilyev S, Schaap RN, Mortensen JD. Hospital survival rates of patients with acute respiratory failure in modern respiratory intensive care units: an international, multicenter, prospective survey. Chest. 1995;107:1083-8.
31. 2 removal for adult respiratory distress syndrome. Am J Respir Crit Care Med. 1994;149:295-305.
32. Villar J, Blanco J, Anon JM, Santos-Bouza A, Blanch L, Ambrós A, Gandía F, Carriedo D, Mosteiro F, Basaldúa S, Fernández RL, Kacmarek RM. The ALIEN study: incidence and outcome of acute respiratory distress syndrome in the era of lung protective ventilation. Intensive Care Med. 2011;37:1932-41.
33. Kikuchi S, Kojika M, Shibata S, Takahashi G, Onodera M, Fujino Y, Suzuki Y, Inoue Y, Endo S. Assessment of high mobility group box 1 values in the early stage after the onset of ALI/ARDS and the outcome. J Iwate Med Assoc. 2009;61:283-93.
34. Zeiher BG, Arigas A, Vincent JL, Dmitrienko A, Jackson K, Thompson BT, STRIVE Study Group. Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study. Crit Care Med. 2004;32:1695-702.
35. Endo S, Sato N, Yaegashi Y, Suzuki Y, Kojika M, Yamada Y, Yoshida Y, Nakadate T, Aoki H, Inoue Y. Sivelestat sodium hydrate improves septic acute lung injury by reducing alveolar dysfunctions. Res Commun Mol Pathol Pharmacol. 2006;119:53-65.